Paris and Boston, January 14, 2025 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Mauna Kea Technologies Announces its 2025 Financial Calendar
read more
Search Results
Raising Pancreatic Cancer Awareness Through Patient Voices
With its Needle-Based Confocal Laser Endomicroscopy Solution, Mauna Kea is Playing a Decisive Role in the Fight Against Pancreatic...
Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador
Paris and Boston, November 20, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Mauna Kea Technologies Announces Review of Strategic Alternatives
Paris and Boston, November 19, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT),...
Mauna Kea Technologies Provides an Update on Its Recent Developments
Paris and Boston, November 13, 2024 – 12:15 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the...
Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance
Major New Study Presented at the World's Largest Gastroenterology Congress Validation of Mauna Kea's Growth Strategy with CellTolerance® in a $6...
Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales
Confirmation of lower breakeven point trajectory with 9% Reduction in Operational Expenses Q3 2024 Sales Growth of +24%1 Driven by...
Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio
Recent clinical study published in Journal of Thoracic Disease supports the combination of Cellvizio with Electromagnetic Navigation Bronchoscopy to...
Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio®
Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio® Formal letter requests...
Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024
Q2 2024 Sales Up 48% vs. Q1 but Down 20% Year-on-Year¹ as U.S. Systems Sales Scheduled for the Second Half of 2024 and Temporary Reimbursement...
Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances
CellTolerance™ is a unique science-based program designed with physicians and dietitians New data presented at Digestive Disease Week...
Mauna Kea Technologies Reports New Evidence Highly Supportive of the Use of Cellvizio for Diagnosing Pancreatic Cysts Presented at DDW 2024
Pancreatic cancer remains difficult to diagnose accurately using conventional methods often leading to late-stage diagnoses or unnecessary...